Background on Capivasertib - now approved for breast cancer

Approval of Capivasertib for PIK3CA/AKT1/PTEN–Altered Breast Cancer: Jason Mouabbi and Carlos DotiПодробнее

CAPItello-291: capivasertib +fulvestrant for AI-resistant HR+/HER2- advanced breast cancerПодробнее

Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 StudyПодробнее

Results of Capitello291 - CapivasertibПодробнее

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast CancerПодробнее

Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancerПодробнее

Capivasertib Approved to Treat Patients with Advanced (HR+/HER2-) Breast Cancer │ PharmacologyПодробнее

Capivasertib + fulvestrant improves progression-free survival in advanced HR+ breast cancer patientsПодробнее

Capivasertib in Advanced Breast Cancer | NEJMПодробнее

Capivasertib for AKT1 E17K-Mutated Metastatic including Breast Cancer: NCI-MATCH EAY131-YПодробнее

Key data from the San Antonio Breast Cancer Symposium (SABCS) 2022Подробнее

Special Session: New Drug Approvals for Metastatic Breast CancerПодробнее

Use of Capivasertib in Relapsed/Refractory HR+ Breast CancerПодробнее

The emerging role of AKT inhibitors in breast cancerПодробнее

Capivasertib for Breast Cancer, Repotrectinib for NSCLC, Enzalutamide for Prostate Cancer,...Подробнее

No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBCПодробнее

Campaigning for Enhertu | Breast Cancer NowПодробнее

Capivasertib Plus Fulvestrant for Patients With Metastatic Hormone-Positive Breast CancerПодробнее

CAPItello-292: capivasertib, palbociclib, and fulvestrant for HR+ endocrine-resistant breast cancerПодробнее